Form 8-K - Current report:
SEC Accession No. 0001558370-22-002898
Filing Date
2022-03-04
Accepted
2022-03-04 17:00:33
Documents
12
Period of Report
2022-03-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K kala-20220302x8k.htm   iXBRL 8-K 32415
  Complete submission text file 0001558370-22-002898.txt   152663

Data Files

Seq Description Document Type Size
2 EX-101.SCH kala-20220302.xsd EX-101.SCH 3148
3 EX-101.LAB kala-20220302_lab.xml EX-101.LAB 15924
4 EX-101.PRE kala-20220302_pre.xml EX-101.PRE 10059
6 EXTRACTED XBRL INSTANCE DOCUMENT kala-20220302x8k_htm.xml XML 4822
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 22715008
SIC: 2834 Pharmaceutical Preparations